Moderna, Inc. (MRNA)
Moderna's personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped
Doctors and patients are excited about the possible breakthrough, but some analysts believe there's too much hype.
Moderna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough
$51.5 billion. That's Moderna's market valuation as of Thursday, marking a more than $18 billion decline from Wednesday's closing valuation of $69.6 billion.
How Moderna's Historic Short Squeeze Upended the AI Chip Trade
Moderna stock surged following positive cancer-vaccine data, burning short sellers and spilling over into the semi sector.
Moderna oncology platform draws Street value after melanoma trial win
Moderna Inc (NASDAQ:MRNA, XETRA:0QF)'s melanoma trial success is prompting Wall Street to assign new platform value to the company's oncology pipeline, Jefferies said, as investors look beyond its COVID-dependent revenue base. The Jefferies note said intismeran vipatamotide (mRNA-4157), an individualized neoantigen therapy (INT) combined with Merck's Keytruda, succeeded in the Phase III INTerpath-001 study evaluating patients with Stage IIB-IV melanoma following complete surgical resection.
Moderna Plunges 20% One Day After Cancer Vaccine Breakthrough Sent Shares Up 177%
Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares have crashed 20% as of 12:00 PM ET on Thursday after delivering one of the biotech sector's most extraordinary single-day moves of 2026.
Moderna is paring back gains, but Merck stock remains a buy
Moderna (MRNA) shares are paring back some of their recent gains on Thursday morning – but a Morgan Stanley analyst believes Merck (MRK) stock remains a buy following blockbuster cancer drug trial results. A recent late-stage clinical trial showcased a combination therapy comprising MRNA's intismeran autogene and MRK's renowned Keytruda as effective in high-risk patients with melanoma.
Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock are down 18% to $142.70 in Thursday midday trading, unwinding a meaningful piece of Wednesday's historic 177% rally.
Cancer vaccine breakthrough at Moderna raises hopes for Scancell's melanoma programme
A landmark trial success for Moderna and Merck's cancer vaccine has strengthened the case for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the immuno-oncology company developing a rival melanoma treatment, according to one broker covering the sector's innovative small-caps. Merck and Moderna said on Wednesday that their phase III INTerpath-001 trial of intismeran autogene, an mRNA-based cancer vaccine, met its endpoints in patients with completely resected stage IIB-IV melanoma.
Moderna stock falls 20% after record rally as valuation concerns emerge
Moderna shares fell sharply in trading on Thursday as investors took profits after the biotechnology company posted its biggest one-day gain following positive Phase 3 cancer vaccine results. The retreat also came as analysts raised their price targets but kept several valuations below Wednesday's closing price, highlighting questions over how much of the clinical breakthrough was already reflected in the stock.
Is Cancer the Next Breakthrough for Moderna After COVID-19?
MRNA's cancer therapy scores a first phase III win, fueling hopes its mRNA platform can drive growth beyond COVID-19 vaccines.
Moderna Stock Rockets Higher After Positive Cancer Vaccine Trial Data
Moderna and Merck delivered positive news about their personalized skin-cancer vaccine Wednesday. Investors bought their shares in droves.
Tempus AI Just Had Their Entire Strategy Validated By Moderna's Vaccine Advance
Tempus AI remains a strong buy, driven by its unique flywheel business model and recent validation of its technology via the Personalis acquisition. TEM's diagnostics and data/applications segments are both growing rapidly, with Q2 2026 revenue up 19.4% YoY and major partnerships fueling its proprietary database. FDA approvals, expanded test offerings, and higher pricing are set to drive significant revenue and margin expansion from 2027 onward.
